Credit Suisse’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,236
| Closed | -$194K | – | 3160 |
|
|
2023
Q2 | $194K | Sell |
7,236
-2,937
| -29% | -$126K | ﹤0.01% | 3096 |
|
|
2023
Q1 | $594K | Buy |
10,173
+711
| +8% | +$35.1K | ﹤0.01% | 2653 |
|
|
2022
Q4 | $483K | Buy |
9,462
+186
| +2% | +$12.9K | ﹤0.01% | 2799 |
|
|
2022
Q3 | $760K | Buy |
9,276
+30
| +0.3% | +$2.24K | ﹤0.01% | 2514 |
|
|
2022
Q2 | $626K | Buy |
9,246
+35
| +0.4% | +$3.21K | ﹤0.01% | 2700 |
|
|
2022
Q1 | $1.02M | Buy |
9,211
+5,068
| +122% | +$632K | ﹤0.01% | 2532 |
|
|
2021
Q4 | $398K | Sell |
4,143
-1,565
| -27% | -$156K | ﹤0.01% | 3979 |
|
|
2021
Q3 | $498K | Buy |
5,708
+110
| +2% | +$11.4K | ﹤0.01% | 3797 |
|
|
2021
Q2 | $866K | Sell |
5,598
-393
| -7% | -$57K | ﹤0.01% | 3497 |
|
|
2021
Q1 | $945K | Sell |
5,991
-8,271
| -58% | -$1.74M | ﹤0.01% | 3357 |
|
|
2020
Q4 | $3.31M | Sell |
14,262
-834
| -6% | -$193K | ﹤0.01% | 2422 |
|
|
2020
Q3 | $3.31M | Sell |
15,096
-520
| -3% | -$127K | ﹤0.01% | 2059 |
|
|
2020
Q2 | $4.44M | Buy |
15,616
+9,603
| +160% | +$2.84M | ﹤0.01% | 1777 |
|
|
2020
Q1 | $1.73M | Sell |
6,013
-1,578
| -21% | -$435K | ﹤0.01% | 2232 |
|
|
2019
Q4 | $2.18M | Buy |
7,591
+4,794
| +171% | +$1.04M | ﹤0.01% | 2533 |
|
|
2019
Q3 | $403K | Sell |
2,797
-3,580
| -56% | -$485K | ﹤0.01% | 3553 |
|
|
2019
Q2 | $572K | Sell |
6,377
-511
| -7% | -$41K | ﹤0.01% | 3319 |
|
|
2019
Q1 | $603K | Buy |
6,888
+2,488
| +57% | +$276K | ﹤0.01% | 3233 |
|
|
2018
Q4 | $618K | Buy |
4,400
+1,329
| +43% | +$224K | ﹤0.01% | 3136 |
|
|
2018
Q3 | $784K | Sell |
3,071
-51
| -2% | -$14.1K | ﹤0.01% | 3036 |
|
|
2018
Q2 | $796K | Buy |
3,122
+49
| +2% | +$12.1K | ﹤0.01% | 3174 |
|
|
2018
Q1 | $619K | Buy |
3,073
+403
| +15% | +$80.4K | ﹤0.01% | 3252 |
|
|
2017
Q4 | $384K | Buy |
2,670
+534
| +25% | +$85.8K | ﹤0.01% | 3540 |
|
|
2017
Q3 | $352K | Buy |
2,136
+1,420
| +198% | +$203K | ﹤0.01% | 3669 |
|
|
2017
Q2 | $97K | Sell |
716
-306
| -30% | -$45.3K | ﹤0.01% | 3723 |
|
|
2017
Q1 | $197K | Sell |
1,022
-169
| -14% | -$27.1K | ﹤0.01% | 3623 |
|
|
2016
Q4 | $168K | Sell |
1,191
-464
| -28% | -$62.7K | ﹤0.01% | 3856 |
|
|
2016
Q3 | $242K | Buy |
1,655
+324
| +24% | +$38.9K | ﹤0.01% | 3740 |
|
|
2016
Q2 | $134K | Buy |
+1,331
| New | +$173K | ﹤0.01% | 4001 |
|
|
2016
Q1 | – | Sell |
-3,172
| Closed | -$630K | – | 4155 |
|
|
2015
Q4 | $630K | Buy |
+3,172
| New | +$687K | ﹤0.01% | 3197 |
|
|
2015
Q3 | – | Sell |
-4,169
| Closed | -$1.7M | – | 4378 |
|
|
2015
Q2 | $1.7M | Buy |
4,169
+2,202
| +112% | +$952K | ﹤0.01% | 2680 |
|
|
2015
Q1 | $903K | Buy |
1,967
+746
| +61% | +$322K | ﹤0.01% | 3059 |
|
|
2014
Q4 | $685K | Buy |
1,221
+700
| +134% | +$398K | ﹤0.01% | 3468 |
|
|
2014
Q3 | $273K | Buy |
521
+116
| +29% | +$65.5K | ﹤0.01% | 3977 |
|
|
2014
Q2 | $282K | Sell |
405
-414
| -51% | -$193K | ﹤0.01% | 4150 |
|
|
2014
Q1 | $380K | Buy |
+819
| New | +$415K | ﹤0.01% | 3917 |
|
Other funds holding KPTI
APM
PAI
Credit Suisse's KPTI Position: Q3 2023 in Review
Credit Suisse sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 7,236 shares — an estimated $194K sold.
Credit Suisse first reported a position in KPTI in Q1 2014 and held it in 36 quarters. The position peaked at $4.44M in Q2 2020. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.
- Credit Suisse reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 7,236 Karyopharm Therapeutics shares in Q3 2023, an estimated $194K.
- Credit Suisse first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 36 quarters.
- Credit Suisse's Karyopharm Therapeutics position peaked at $4.44M in Q2 2020.
- 118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.